Immix Biopharma · pitchdeck
Immix Biopharma | Investor Presentation Deck | 61 slides
61 pages · 4 arc beats · 3 loops
Immix Biopharma | Investor Presentation Deck | 61 slides
Immix Biopharma · 2023-11 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
15101520253035404550556061
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 61 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Attention 3 slides 100% 3/3 slides 100% 3/3 slides · 11 hits — 0/3 slides
66.7% 2/3 slides 33.3% 1/3 slides 100% 3/3 slides — 0/3 slides
Interest 6 slides 100% 6/6 slides 100% 6/6 slides · 31 hits — 0/6 slides
83.3% 5/6 slides 66.7% 4/6 slides 100% 6/6 slides 66.7% 4/6 slides Desire 8 slides 100% 8/8 slides 100% 8/8 slides · 43 hits — 0/8 slides
50% 4/8 slides 75% 6/8 slides 100% 8/8 slides — 0/8 slides
Action 44 slides 100% 44/44 slides 100% 44/44 slides · 215 hits — 0/44 slides
38.6% 17/44 slides · 20 hits 50% 22/44 slides 100% 44/44 slides 15.9% 7/44 slides Slide inventory
61 every slide · same image gating as the playbook
03
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailBeat · Attention
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.other
Open slide detailBeat · Interest
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.present_solution
Open slide detailBeat · Interest
06
Uses a hub-and-spoke diagram to illustrate the negative impacts of a central problem.frame_problem
07
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.present_solution
08
The slide uses a schematic diagram to map specific protein domains to their functional benefits.present_solution
09
The slide uses academic citations to validate the mechanism of action for their CAR-T design.present_solution
10
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of NXC-201.compare_peers
Open slide detailBeat · Desire
11
The slide compares HSL (Heavy-chain-led) vs LSH (Light-chain-led) configurations using bar charts for expansion and cytotoxicity metrics.present_solution
Open slide detailBeat · Desire
13
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.compare_peers
Open slide detailBeat · Desire
14
The slide uses a biological structural comparison to highlight the unique binding domain of the NXC-201 product.present_solution
Open slide detailBeat · Desire
15
Includes comparative data charts for transduction efficiency and signaling, and flow cytometry data for anti-exhaustion.present_solution
Open slide detailBeat · Desire
16
The slide uses a longitudinal timeline comparison to highlight the superior safety and efficacy profile of NXC-201.compare_peers
Open slide detailBeat · Desire
17
The chart illustrates the correlation between the peak of HBI0101 cells and the subsequent drop in dFLC, a marker for AL Amyloidosis.show_traction
Open slide detailBeat · Desire
18
The slide uses a causal chain to link cellular pathology to systemic organ damage.frame_problem
Open slide detailBeat · Action
19
The slide uses a grouped bar chart format to highlight clinical superiority. Includes a disclaimer about cross-trial comparisons.compare_peers
20
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.compare_peers
21
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.compare_peers
22
Includes a footnote citing FDA approval precedents for similar single-arm studies.plan_implementation
23
Uses a visual icon-grid to represent market expansion.size_opportunity
24
Includes detailed source citations in the footer; uses color-coded bars to represent different drug therapies.show_traction
25
The slide uses a two-column layout to separate milestones by drug candidate.plan_implementation
26
The slide uses a standard pharmaceutical pipeline table format with clinical and preclinical segments.show_traction
Open slide detailBeat · Action
27
Includes a comparison table of clinical outcomes (ORR/CR) between NXC-201 and competitors.argue_timing
Open slide detailBeat · Action
28
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.size_opportunity
Open slide detailBeat · Action
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.compare_peers
Open slide detailBeat · Action
31
The chart uses a grouped bar structure to compare NXC-201 (green) against competitors (blue/red) across three categories: No BCMA, Yes BCMA, and Overall.compare_peers
Open slide detailBeat · Action
32
The slide uses a structured comparison table to highlight clinical advantages. It includes a disclaimer about cross-trial comparisons.compare_peers
Open slide detailBeat · Action
33
The slide uses a comparative structure to present data for two distinct indications side-by-side.show_traction
Open slide detailBeat · Action
34
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.show_traction
Open slide detailBeat · Action
35
The table displays clinical safety data for NXC-201, specifically focusing on Cytokine Release Syndrome and Immune cell associated Neurotoxicity.analyze_data
Open slide detailBeat · Action
36
The slide highlights specific safety metrics for a competitor's product, likely to contrast with the presenter's own product profile.compare_peers
Open slide detailBeat · Action
37
The diagram illustrates a dose-escalation process leading to the RP2D.plan_implementation
Open slide detailBeat · Action
38
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.transition
Open slide detailBeat · Action
39
Includes scientific diagrams of molecular pathways and bar/line charts showing efficacy data.present_solution
Open slide detailBeat · Action
40
Slide presents three distinct preclinical data sets: survival in STS, tumor response in STS, and survival in KPC pancreatic cancer models.show_traction
Open slide detailBeat · Action
41
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.show_traction
Open slide detailBeat · Action
42
Includes both internal unpublished data and external reference data from Winograd et al. (2015).show_traction
Open slide detailBeat · Action
44
Includes spider plots/swimmer-style plots for tumor response and bar charts for best percentage change.show_traction
Open slide detailBeat · Action
45
The slide uses a scatter plot to map clinical trials and a table to summarize treatment outcomes across lines of therapy.compare_peers
Open slide detailBeat · Action
46
The slide presents clinical data for a small sample size (n=4) in a highly pre-treated patient population.show_traction
Open slide detailBeat · Action
47
Shows two parallel tracks: monotherapy and combination therapy with tislelizumab.plan_implementation
Open slide detailBeat · Action
49
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.present_solution
Open slide detailBeat · Action
50
The slide uses a process-to-product mapping structure.present_solution
Open slide detailBeat · Action
51
Includes technical diagrams of the drug delivery vehicle and comparative histology/survival data.present_solution
Open slide detailBeat · Action
52
Includes two sets of charts: tumor volume over time and survival curves.show_traction
Open slide detailBeat · Action
53
Includes multiple citations and diagrams illustrating the mechanism of action and clinical efficacy.present_solution
Open slide detailBeat · Action
54
The slide uses a numbered list format to present key value propositions for the company's pipeline.summarize
Open slide detailBeat · Action
57
The slide uses a serpentine process flow (1-5 left-to-right, 6-10 right-to-left).plan_implementation
Open slide detailBeat · Action
58
Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.compare_peers
Open slide detailBeat · Action
59
The slide uses a combination of expert testimonials and a comparative table of clinical trials to validate the outpatient administration model.show_traction
Open slide detailBeat · Action
60
The slide uses a bar chart to contrast the combined sales of two groups of drugs, implying a large market opportunity for TSTx.size_opportunity
Open slide detailBeat · Action
61
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.compare_peers
Open slide detailBeat · Action